Can Empagliflozin Improve Nerve Function in Type 2 Diabetes?

Summary:

In patients with diabetic peripheral neuropathy, the addition of empagliflozin 10 mg daily significantly reduced HbA1c, fasting blood glucose, and serum creatinine levels, while improving nerve conduction velocity and eGFR compared to a placebo group continuing their existing diabetes regimen, though it was associated with no reported significant adverse effects in this study.

Clinical Context

Diabetic peripheral neuropathy affects roughly half of people with long-standing type 2 diabetes and is driven by chronic hyperglycaemia, microvascular ischaemia, oxidative stress and the accumulation of advanced glycation end-products within peripheral nerves. Beyond lowering glucose, SGLT2 inhibitors such as empagliflozin reduce body weight, blood pressure and intraglomerular pressure and carry established cardiorenal benefits, which raises the question of whether they also modify nerve function. The biological rationale rests on improved glycaemic control combined with pleiotropic effects on inflammation, oxidative stress and the microvasculature that supplies the vasa nervorum. Direct evidence for a neurological benefit of SGLT2 inhibition is limited, and this short double-blind randomised trial set out to test whether adding empagliflozin to usual care improves electrophysiological measures of nerve function over 20 weeks.

Clinical Pearls

• Glycaemic improvement confirmed: Adding empagliflozin 10 mg once daily for 20 weeks significantly lowered both HbA1c and fasting blood glucose versus placebo, confirming the expected on-target metabolic effect.
• Electrophysiological signal: Nerve conduction velocity rose and distal latency fell in the empagliflozin arm, an objective signal that the drug may influence nerve conduction rather than symptoms alone.
• What did not change: Response amplitude and clinical examination scores did not differ significantly between groups, tempering any claim of axonal recovery over this short period.
• Renal shift with clean safety: Serum creatinine fell and eGFR rose, consistent with the known haemodynamic renal effects of SGLT2 inhibition, and no major adverse events were reported.

Practical Application

Empagliflozin is already a guideline-supported option for many adults with type 2 diabetes, particularly those with cardiovascular or renal indications, so a possible neurological benefit would be a welcome bonus rather than a stand-alone reason to start it. Clinicians should not yet present SGLT2 inhibitors as a treatment for established neuropathy: the gains here were in electrophysiological surrogates over 20 weeks, with no change in clinical examination scores. The 10 mg once-daily dose used in the trial matches usual prescribing. Routine precautions apply: assess renal function, counsel on genital mycotic infection and euglycaemic ketoacidosis risk, and consider volume status in frail or older patients. Foot care, glycaemic optimisation and symptom-directed neuropathy management remain the foundation of care.

Broader Evidence Context

SGLT2 inhibitors have reshaped type 2 diabetes care through cardiovascular and renal outcome trials such as EMPA-REG OUTCOME for empagliflozin, but their effect on diabetic neuropathy is far less established. Tight glycaemic control slows neuropathy progression more convincingly in type 1 than in type 2 diabetes, where intensive glucose lowering alone has produced only modest effects on nerve endpoints. Mechanistic interest in SGLT2 inhibitors for nerve health centres on weight loss, reduced oxidative stress and microvascular benefit. These findings are consistent with prior work suggesting that metabolic and microvascular improvement may translate into measurable nerve conduction changes, but they remain preliminary and hypothesis-generating and should be weighed alongside larger, neuropathy-focused trials before firm conclusions are drawn.

Study Limitations

• The 20-week duration is too short to capture meaningful axonal regeneration or progression of a chronic, slowly evolving complication.
• Outcomes relied on electrophysiological surrogates such as nerve conduction velocity and latency rather than hard clinical endpoints like ulceration, falls or validated symptom scores.
• Single-trial design with limited sample size; the outcome data report directions of effect without effect sizes or confidence intervals.
• Improvements in glycaemia, renal indices and nerve conduction are confounded, so better glucose control alone could explain part of the neurological change and the drug’s independent effect is hard to isolate.
• No long-term durability or safety data, and unchanged clinical examination scores leave the patient-level relevance uncertain.

Bottom Line

Over 20 weeks, adding empagliflozin 10 mg daily improved glycaemic control, renal indices and nerve conduction velocity in type 2 diabetic neuropathy, with no major adverse effects but no change in clinical examination scores. The signal is encouraging and biologically plausible, yet rests on short-term surrogates. Empagliflozin remains a sound choice for its established cardiorenal benefits; its role as a dedicated neuropathy treatment awaits longer trials using clinical endpoints.

Source: Vafaeinasab, Mohammadreza, et al. “The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type II Diabetes: A Double Blind Randomised Clinical Trial.” Endocrinol Diabetes Metab. Read article here.

🔗 Related reading

• EMPA-REG OUTCOME: Empagliflozin Cardiovascular Benefit
• DAPA-HF: SGLT2 Inhibition in Heart Failure